ABREVA Drug Patent Profile

Which patents cover Abreva, and when can generic versions of Abreva launch?

Abreva is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in ABREVA is docosanol. There are five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the docosanol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abreva

A generic version of ABREVA was approved as docosanol by P AND L on November 19^th, 2018.

Summary for ABREVA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ABREVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941-001	Jul 25, 2000		OTC	Yes	Yes

International Patents for ABREVA

See the table below for patents covering ABREVA around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	300354
Spain	2299173
Japan	H09506612

Supplementary Protection Certificates for ABREVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0428642	300354	Netherlands		300354, 20100416, EXPIRES: 20150415
0428642	07C0081	France		PRODUCT NAME: DOCOSANOL; REGISTRATION NO/DATE IN FRANCE: NL 33457 DU 20070821; REGISTRATION NO/DATE AT EEC: 18517 DU 20031114
0428642	57/2007	Austria		PRODUCT NAME: DOCOSANOL; NAT. REGISTRATION NO/DATE: 1-27014 20070518; FIRST REGISTRATION: SE 18517 20031114

ABREVA Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Current Investment Scenario for Abreva?

Abreva (docosanol 10%) is an over-the-counter (OTC) drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of cold sores caused by herpes simplex virus. Marketed primarily under the brand name Abreva by GlaxoSmithKline (GSK), it holds a dominant position in the OTC herpes treatment segment.

Market Position & Sales:
Abreva generated approximately $470 million in global sales in 2022, representing a significant share of OTC herpes treatments worldwide. U.S. sales account for roughly 75% of total revenue, with the remaining deriving from international markets.

Market Competition:
Although the drug is the only OTC treatment approved by the FDA for cold sores, prescription options like acyclovir or valacyclovir are available but typically require medical consultation. OTC alternatives include products claiming symptom relief but lack FDA approval for antiviral activity.

Patent & Regulatory Status:
Abreva's patent expired in 2020, allowing potential generic competition. Despite this, GSK maintains market share through brand recognition, shelf positioning, and consumer trust. Regulatory pathways for generics received FDA approval for generic docosanol formulations in late 2021, setting the stage for increased competition.

Key Investment Considerations:

• Brand loyalty and high consumer demand sustain current sales.
• Patent expiration exposes vulnerability to generics, risking price erosion.
• International expansion efforts could offset U.S. generic entry impact.

What Are the Fundamental Drivers of Abreva’s Market Performance?

Market Demand & Consumer Behavior:
Cold sore frequency varies per individual, with frequent sufferers seeking effective OTC remedies. Consumer preference for quick-acting, proven treatments favors Abreva, which claims to shorten healing time when applied at the first sign of symptoms.

Sales Dynamics:
Abreva's core sales driver is its efficacy label, supported by FDA approval. Its OTC status facilitates widespread availability and brand dominance. Marketing efforts emphasize early treatment effectiveness, reinforcing consumer trust.

Competitive Landscape:
Patents expired in 2020 initiated a wave of generic entrants. Despite this, GSK’s marketing and consumer recognition maintain sales. The introduction of generics generally places downward pressure on prices, which can impact profit margins.

Regulatory Environment:
The FDA’s approval of generic docosanol formulations in 2021 adheres to standard bioequivalence requirements, leading to increased competitive pressure. Future regulatory changes or new approvals for alternative OTC or prescription therapies could shift the landscape.

Pricing & Profitability:
Pricing for branded Abreva in the U.S. averages $10.50 for a 12-gram tube, compared to generics at approximately $7.50. Gross margins traditionally hover around 60%, but are threatened by generics and price competition.

Growth Opportunities:

• International markets: expansion into European and Asian markets could augment revenue streams.
• New formulations: research into combination therapies or topical delivery systems may foster growth.
• Branding: strengthening consumer awareness can deter generic market share erosion.

What Are the Risks Associated with Abreva Investment?

• Generic Competition: Entry of lower-priced generics can significantly reduce sales volume and margins.
• Regulatory Changes: Restrictions on OTC claims or approval delays for new indications could limit growth.
• Patent Challenges: Court filings contesting patent validity might accelerate generic entry.
• Market Saturation: The OTC herpes treatment segment is mature, with limited growth potential.

What Financial Metrics Are Relevant for Abreva?

Metric	2022	Notes
Revenue	~$470 million	U.S. dominant, international growing
Gross Margin	Approx. 60%	Decline possible with generics
Operating Margin	Estimated 30%	Reflects marketing and distribution costs
R&D Expense	Minimal	Primarily for formulation improvements

Conclusion

Abreva remains a leading OTC treatment for cold sores, supported by brand recognition and proven efficacy. The patent expiry in 2020 and subsequent approval of generic formulations in 2021 threaten to dilute profitability. International expansion and new product development represent potential growth avenues, but competitive pressures persist. Investors should weigh the resilience of brand loyalty against the risks posed by generics and regulatory shifts.

Key Takeaways

• Abreva's U.S. sales benefit from high consumer trust and FDA approval but face headwinds from generic competition post-patent expiration.
• The drug's market share remains substantial due to brand recognition despite the availability of cheaper alternatives.
• Future growth hinges on international expansion, innovative formulations, and maintaining marketing effectiveness.
• Regulatory and patent challenges pose ongoing risks that could accelerate generic penetration.
• Margins are susceptible to dilution as prices converge with generics; strategic brand positioning remains critical.

FAQs

1. How long does Abreva typically take to work?
Effective application at the first sign of symptoms can shorten healing time by approximately 1.5 days compared to placebo.

2. Are there effective prescription alternatives?
Yes, prescription antivirals like acyclovir and valacyclovir are effective but usually require a healthcare provider’s prescription and are not OTC.

3. What is the status of patent protection?
Abreva’s primary patent expired in 2020, opening the market to generics approved in late 2021.

4. Can Abreva be used for other herpes simplex virus infections?
No, Abreva is FDA-approved specifically for cold sores caused by herpes simplex virus type 1.

5. What growth strategies could extend Abreva’s market life?
International expansion, combination product formulations, and enhanced marketing are key strategies to sustain revenue.

---

Sources

1. GSK Annual Report 2022.
2. FDA Drug Database, 2022.
3. MarketWatch, OTC Herpes Treatment Market Analysis, 2022.
4. IQVIA Data, 2022.
5. FDA Generic Drug Approvals, 2021.